Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 9,901–10,000 of 10,906
Yang, F. (2024) · Transactions on Materials Biotechnology and Life Sciences · doi:10.62051/dgf2a481
KEJADIAN MIOKARDITIS PASCA PEMBERIAN VAKSIN COVID-19 BERBASIS mRNA
Indonesia, U. M., & Tambunan, R. T. H. (2021) · Majalah Ilmiah METHODA · doi:10.46880/methoda.vol11no3.pp176-184
Zamora, J. I., López-Martínez, M., Patricio-Liébana, M., León-Román, J. C., Bermejo, S., Vergara, A., Agraz, I., Ramos-Terrades, N., Azancot, M. A., Toapanta, N., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062420 · Cited by 1
mRNA Vaccines as Member of Biotechnology-Based Vaccines
Harisa, G. I., & Alzahrani, M. M. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_15
VACCINATION CONTRE LA COVID-19 ET RISQUE ALLERGIQUE : DES DONNEES POUR LA MEDECINE GENERALE
ORCEL, V., ADELINE-DUFLOT, F., BRETON, J. L., et al. (2021) · EXERCER · doi:10.56746/exercer.2021.170.79
Analysis of adverse effects caused by mRNA vaccines used in the fight against COVID-19
Pitoscia, G. O., & Faria, T. V. (2021) · MedNEXT Journal of Medical and Health Sciences · doi:10.54448/mdnt21602
van der Meeren, L. E., Broekhuizen, M., van den Bosch, T. T. P., et al. (2024) · Journal of Patient Safety · doi:10.1097/pts.0000000000001304
Refining the role of behavioural and social sciences in pandemic response post-COVID-19
Graso, M., Aquino, K. F., Baral, S., Berg, N., Clark, C. J., Conway, L. G., Dolan, P. J., Grover, S. L., Fousiani, K., Kitz, C. C., et al. (2026) · Nature Human Behaviour · doi:10.1038/s41562-026-02506-4 · Cited by 1
Abou-Saleh, H., Abo-Halawa, B. Y., Younes, S. N., et al. (2022) · medRxiv · doi:10.1101/2022.05.08.22274817
Research and Development of HFMD Vaccines
Zhao, H. (2024) · Springer eBooks · doi:10.1007/978-981-99-9660-5_6
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0011
Precision recruitment for high-risk participants in a COVID-19 research studyPreprint
Mezlini, A. M., Caddigan, E., Shapiro, A. D., et al. (2022) · medRxiv · doi:10.1101/2022.03.03.22271504
Yang, P., Jiang, X., Zhang, Y., Kang, W., Liu, Y., Gang, Y., Li, R., Wang, W., Wang, T., Zhang, W., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12828-3
“The rapid immunological recall has-tens the emergence of symptoms [37, 38].”
Dose-dependent interferon programs in myeloid cells after mRNA and adenovirus COVID-19 vaccinationPreprint
Eryilmaz, G. N., Yazici, Y. Y., Marcheş, R., Mimitou, E. P., Kenyon‐Pesce, L., Handrjek, K., Jangra, S., Schotsaert, M., García‐Sastre, A., Kuchel, G. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.15.668720
Sugaya, T., Takagi, T., Uchiyama, K., Kajiwara‐Kubota, M., Asaeda, K., Okumura, K., Inaba, T., Naito, Y., & Itoh, Y. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.22-60
Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases
Bakrania, A. K., Lefebvre, A.-T. N., de Vries, R., Laflamme, M. A., Jaeckel, E., He, H. H., Radvanyi, L. G., Hedtrich, S., Sahay, G., Blakney, A. K., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01476-y · Cited by 3
Safrai, M., Rottenstreich, A., Herzberg, S., Imbar, T., Reubinoff, B. E., & Ben‐Meir, A. (2022) · Austin Journal of Obstetrics and Gynecology · doi:10.26420/austiniobstetgynecol.2022.1204
van der Goes, T. I. F. (2021) · Revista de la Facultad de Medicina UNAM · doi:10.22201/fm.24484865e.2021.64.1.01
Hargadon, K. M. (2021) · Journal of Global Health Reports · doi:10.29392/001c.26142
Peña-Galo, E. M., Alcaine, J. M. T., Gracia-Carrasco, E., & Alcedo-González, J. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.01.004
A Bioorthogonal Desilylation System Potentiates mRNA Therapeutics in Tumors
Zhang, M., Wang, C., Xu, X., Ding, Z., Chen, J., Guo, Z., & Liu, Z. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09548
Prasad‐Reddy, L., Dahal, A., & Zimmer, A. J. (2026) · Springer eBooks · doi:10.1007/978-1-0716-5464-4_15
The Systematic Research of The Comparison of Moderna Covid-19 Vaccine and Pfizer Covid-19 Vaccine
Wang, Q. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v45i.7384
SARS-CoV-2 Vaccine Immunogenicity in Patients with Autoimmune Inflammatory Rheumatic Diseases
Furer, V. (2022) · touchREVIEWS in RMD · doi:10.17925/rmd.2022.1.2.38
Insights into the T-cell response to SARS-CoV-2
Kadi, C., Najimi, N., Zakaria, M., Bakri, Y., Noureddine, E., & Fouad, S. (2023) · European Journal of Inflammation · doi:10.1177/1721727x231211458
A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferretsPreprint
Martins, M., do Nascimento, G. M., Conforti, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.29.510112
Ahmed, J. I., Krosta, S. J., Reimer, M. N., Cheung, W., Mesa, C., Lopez, C., Chua, R. J., Alsattari, F., Robinson, A., Manguiat, K., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529134 · Cited by 1
Confirmed cases of COVID-19 after vaccination against COVID in health personnel in Bogotá, Colombia
Porras, A., Sánchez-París, R., López-Devia, W., Moreno-Perilla, Z., Jurado-Zambrano, R., Caina, C. L.-J. C. C. L.-J., Sefair, C., Ramos, N., Otero-Cadena, M., & Lievano, R. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.078
Audigé, A., Amstutz, A., Schuurmans, M. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317965
Alshaikh, R. A., Cronin, D. J., Hughes, D. A., & O’Driscoll, C. M. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107652
Yao, G., Wang, F., Zhu, Y., & Sun, R. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-1002
Suzuki, T., Kanemitsu, Y., Sugimoto, N., Masaki, K., Akamatsu, T., Tsurumaki, H., Majima, S., Ito, K., Iwata, T., Shimizu, H., et al. (2026) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2026.18.3.362 · Cited by 1
“3,4 However, many serious adverse events have been reported after COVID-19 mRNA vaccination, including anaphylaxis, myocarditis, and thrombosis.”
Ma, G., Xie, S., Zhao, L., & Kang, J. L. (2026) · Journal of the American Statistical Association · doi:10.1080/01621459.2026.2682540
ADVANCEMENTS IN NANOPARTICLE-BASED RNA THERAPEUTICS AND RNA DELIVERY SYSTEMS
Al-Hamdani, M., Noori, S., & Kassem, A. B. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.327759 · Cited by 1
Tong, T., D’Addabbo, A., Xu, J., Chalwa, H., Nguyen, A., Ochoa, P., Crispin, M., & Binley, J. Μ. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.02.543368
Adriana, S., Amiruddin, R., Abullah, A. Z., Ida Leida, M., Suriah, S., & Jafar, N. (2024) · International Journal of Chemical and Biochemical Sciences · doi:10.62877/19-ijcbs-24-25-19-19
Draycheva, A., Millecam, J., & Caba, E. (2026) · International Journal of Toxicology · doi:10.1177/10915818261446630
D’Amico, C., Miska, M., Saarinen, S., Säkkinen, V., & Kostiainen, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.25.734245 · Cited by 1
“(1) The clinical validation of mRNA-based vaccines against SARS-CoV-2 demonstrated that in vitro-transcribed mRNA can direct protein synthesis at therapeutically relevant levels in humans, accelerating interest in extending the modality to more demanding indications.”
Poleva, I., Szomolai, E., Hegedus, B., et al. (2023) · Journal of Cutaneous and Aesthetic Surgery · doi:10.4103/jcas.jcas_93_23
COVID-19 – La nueva cara de la desigualdad: Lecciones aprendidas a 2 años del inicio de la pandemia
Cortés-Telles, A., Figueroa‐Hurtado, E., & Ortíz‐Farias, D. L. (2022) · Kompass Neumología · doi:10.1159/000521502
Huguet, M., Boigués, M., Sorigué, M., Blanco, J., Quirant‐Sánchez, B., Ferra, C. M., Huguet, M., Boigués, M., Morgades, M., Felip, E., et al. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2023.10.016
Furst, L. E., Hill, H. R., & Lapine, T. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00258-2
Xu, Y., Zhang, X.-B., & Zhang, J.-P. (2026) · Human Gene Therapy · doi:10.1177/10430342261454725
Zhang, Y., Yu, Q., Zhao, Q., Shi, Z., Wang, Z., Duan, X., Zhao, Y., Zhang, Y., Ye, M., Wang, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9206353/v1
Modelling the impact of vaccination on SARS-CoV-2 transmission in EnglandPreprint
Derqui, N., Mishra, S., Hinsley, W. R., Bhatt, S., & Laydon, D. J. (2024) · medRxiv · doi:10.1101/2024.09.06.24313210 · Cited by 1
COVID-19 In United States: Statistical Analysis and Inferences From the Empirical DataPreprint
Rethnakar, N. (2021) · Research Square · doi:10.21203/rs.3.rs-1084057/v1
Computational Assessment of Plant-Derived Alkaloids for Anti-SARS-CoV-2 Properties
Abhinav., M., & Karthika, K. (2026) · Sciences of Phytochemistry · doi:10.58920/sciphy0502631
Borkens, Y. (2022) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-022-01554-0
Chung, Y., Murugan, V., Beyene, K. M., & Chen, D. (2025) · Journal of Data Science · doi:10.6339/25-jds1199
Lapi, F., Marconi, E., Domnich, A., Cricelli, I., Rossi, A., Grattagliano, I., Icardi, G., & Cricelli, C. A. (2024) · Infectious Disease Reports · doi:10.3390/idr16020021 · Cited by 1
Gupta, J., & Kumar, R. (2026) · Current Research in Translational Medicine · doi:10.1016/j.retram.2026.103577 · Cited by 1
Fleury, H. J. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-78221-3.00008-2
Adverse events of COVID-19 vaccines: Insights from primary health care centers in Qatar
Zaidan, M., Isleem, N., Singh, R., Abdeen, S., Alah, M. A., Ibrahim, M. I. M., Abdulmajeed, J., Al-Nuaimi, A. A., & Al‐Kuwari, M. G. (2025) · Qatar journal of public health. · doi:10.5339/qjph.2025.4
Meyer-Arndt, L., Braun, J., Fauchère, F., et al. (2022) · medRxiv · doi:10.1101/2022.02.06.22270550 · Cited by 1
COVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve the Pandemic
Romine, J. A. S., Kolodziej, S. A., Vetter, T., & Dux, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_8
COVID-19 Incidence and Disease Course Among Patients at an Allergy Department
van der Aa, L. E., van Egmond, I. S., van der Sluijs, M., et al. (2023) · Therapeutic Advances in Allergy and Rhinology · doi:10.1177/27534030231172391
Coronavirus Pandemic: An Update on the Transmission, Diagnosis, Clinical Features and Managment
Alqahtani, S. S., Menachery, S. J., Banji, O. J. F., Meraya, A. M., Albarraq, A. A., Makeen, H. A., Banji, D., Syed, M. H., Yasmeen, A., Shoaib, A., et al. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i37a31994
Ogbondah, B. O., Owhonda, G. C., Luke, A., Jaja, I. D., Green, P., & Pius, O. M. (2023) · Ibom Medical Journal · doi:10.61386/imj.v16i2.307
Tangsathapornpong, A., Nanthapisal, S., Fukpho, W., Bunjoungmanee, P., Neamkul, Y., Pontan, K., Boonyarangkul, A., Wanpen, S., Thongphubeth, K., Tharabenjasin, P., et al. (2026) · Vaccines · doi:10.3390/vaccines14040348
“Participants received a 100 µ g single intramuscular dose (0.5 mL) of the mRNA-1273 COVID-19 vaccine, manufactured by Moderna [22].”
InfluentialRocha, A., Milan, E. P., Caminha, R. O. D. C., et al. (2024) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v27i1.613_port
Mohsenzadeh, A., Pourasgar, S., Borji, S., Bavari, S., Moghadam, E. E., Tanha, H. R., Mohsenzadeh, H., Kamali, K., Moghadam, Z. B., & Sabati, H. (2022) · Journal of Current Biomedical Reports · doi:10.61186/jcbior.3.3.172
das Chagas, R. R., Brasil, R. D. V., Freitas, H. R., de Carvalho, G. B., Gantus, M. A. V., Fortes, F. D. S. D. A., & Cardozo, S. V. (2025) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2025.7.5.2380
“These associations align with prior evidence indicating that the absence of vaccination increases the risk of intense systemic and respiratory symptoms, which are potentially linked to heightened viral loads and unregulated inflammatory responses [1], [2].”
Advanced Nanoparticles for Vaccine Development
Dhanya, S. (2026) · Advanced structured materials · doi:10.1007/978-981-92-1034-3_8
Neurological Complications after COVID-19 Vaccination
Мухсиновна, Х. Х., Rashidova, N., & Salimjonov, J. (2024) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-024-01624-8
Wettengel, J. M., Strehle, K., von Lucke, C., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01768-23
O’Hare, B., Ibrahim, H., & Revelle, P. (2025) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2025.1607642
Bør sykehjemsbeboere uten samtykkeevne vaksineres mot covid-19?
Kittang, B. R. (2021) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.20.0401
mRNA therapeutics for restoring immune tolerance in autoimmune diseases
Zouali, M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104776
Gupta, R. K., Alugupalli, K. R., & COWELL, J. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1816148 · Cited by 2
Harrison, D. A., Watkinson, P., Doidge, J., Shankar‐Hari, M., Mouncey, P. R., Patone, M., Coupland, C. A. C., Hippisley‐Cox, J., & Rowan, K. (2022) · medRxiv · doi:10.1101/2022.10.03.22280649
Barnay, M., Foubert‐Samier, A., Violleau, M., Salort‐Campana, E., Cintas, P., Laforêt, P., Mathis, S., Péréon, Y., Tard, C., Sirma, F., et al. (2025) · Revue Neurologique · doi:10.1016/j.neurol.2025.04.007
Ajobiewe, H. F. (2023) · Texila international journal of public health · doi:10.21522/tijph.2013.11.02.art011
COVID‐19: Neurology Perspective
Keyhanian, K., Umeton, R. P., Mohit, B., McNeilly, B., & Ghasemi, M. (2022) · Wiley eBooks · doi:10.1002/9781119789741.ch15
The Should Healthcare Facilities Mandate COVID-19 Vaccination of its Employees?
Rao, S., & Singh, M. (2021) · DHR Proceedings · doi:10.47488/dhrp.v1is4.17
Regulatory and translational challenges in biotechnology-driven drug delivery
Suryawanshi, S. S., Patil, V. M., Kudale, P. P., Nangude, M. S., Doke, R. R., Patil, P. P., Muleva, G., Vinchurkar, K., Kothawade, S. N., & Mendhi, S. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40620-1.00006-6 · Cited by 1
Singh, T., Padubidri, J. R., Shetty, P. H., et al. (2024) · F1000Research · doi:10.12688/f1000research.145713.2
de Bruyn, G., Adhikarla, H., Brackett, C., Jia, Y., Premkumar, L., Mudrak, S. V., Sawant, S. S., Zhang, D., Chicz, R. M., Sridhar, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01203-z
Estimated effect of COVID-19 vaccine in people with epilepsy
Kuroda, N. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108072
Zhang, H., Clegg, L., Matthews, S., Chang, Y., Aksyuk, A. A., Francisco, D., Ghosh, S., Soboleva, K., Puri, A., Ramesh, M., et al. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01423-3
Lambo, J., Keli, S., Kaplan, S. K., Njideaka-Kevin, T., Arja, S. B., Altahir, A. K. O., Olonade, I., & Kumar, R. (2024) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2024.2399108
Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers
Lane, M. J., & Lane, S. (2021) · The Hematologist · doi:10.1182/hem.v18.6.202163
Coronavirus disease (COVID-19) in patients with hematologic malignancy
Gong, I. Y., & Hicks, L. K. (2023) · Canadian Hematology Today · doi:10.58931/cht.2023.2231
Evaluation of Binding and Neutralizing Antibodies for Inactivated SARS-CoV-2 Vaccine Immunization
Zhao, H., Jiang, G., Li, C., et al. (2024) · Diseases · doi:10.3390/diseases12040067
Sanjeev, A., Hannigan, C., Garrity, R., Kamalakkannan, D. S., Clendaniel, V., Mantri, M., Glass, Z., Kasiewicz, L. N., Leipheimer, J., Khan, Z., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201722 · Cited by 1
“As the GAG cap-1 analog has an adenine in position 1, 28 we rationalized that altering T7 RNAP preference for GTP as initiating nucleotide might result in improved capping.”
Yu, H., Yang, Y., Lin, P., Liu, C., Wen, Y., Fang, Z., Hu, Z., & Huang, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.27.684966
Pan, T., Sf, Y., Chu, R., Zhang, F., Yang, Y., Jq, L., Lü, Y., & He, J. F. (2026) · Advanced Functional Materials · doi:10.1002/adfm.77225
Müller, B., Padberg, I., Lorke, M., Brinks, R., Cripps, S., Gomes, M. G. M., Haake, D., & Ioannidis, J. P. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-36265-z · Cited by 10
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.